Ozempic and Gastroparesis: What Is Stomach Paralysis and Who Is at Risk?
Gastroparesis — commonly called stomach paralysis — is a debilitating condition in which the stomach cannot empty itself normally. Thousands of patients who used Ozempic, Wegovy, or related GLP-1 drugs have reported developing severe gastroparesis or having a pre-existing mild condition dramatically worsen after starting these medications. Lawsuits against Novo Nordisk and Eli Lilly allege these companies failed to adequately warn about this risk.
In This Article
What Is Gastroparesis
Gastroparesis is a condition in which the stomach muscles slow or stop functioning, preventing food from moving into the small intestine at a normal rate. Symptoms include nausea, vomiting, feeling full quickly, bloating, abdominal pain, and malnutrition. Severe cases require hospitalization and tube feeding. Gastroparesis can be temporary or permanent, and some patients who developed it while on Ozempic have not fully recovered even after stopping the drug.
How GLP-1 Drugs Like Ozempic Trigger Gastroparesis
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) work by slowing gastric emptying — deliberately and as part of their intended mechanism of action. This slowing of digestion is part of how these drugs create feelings of fullness and reduce appetite. However, in some patients, particularly those with pre-existing diabetic neuropathy or subclinical gastroparesis, this pharmacological effect can trigger clinically significant gastroparesis that persists long after stopping the medication. Critics argue that Novo Nordisk and Eli Lilly downplayed this risk in their labeling.
Developed gastroparesis after using Ozempic or Wegovy?
Find out if you may qualify — free case review.
Check Eligibility arrow_forwardSymptoms and Diagnosis of GLP-1-Related Gastroparesis
Gastroparesis symptoms related to Ozempic use typically begin within weeks to months of starting the drug and may be severe enough to require emergency care. Common symptoms include persistent nausea and vomiting (often vomiting food eaten hours before), feeling full after only a few bites, bloating and abdominal discomfort, acid reflux, and unintended weight loss from inability to eat. Gastroparesis is typically diagnosed with a gastric emptying study — a nuclear medicine scan showing how quickly food leaves the stomach.
Legal Claims: Who Has Filed and Why
The first Ozempic gastroparesis lawsuits were filed in 2023, and hundreds of additional cases have been consolidated in a federal MDL. Plaintiffs allege that Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro) knew of the gastroparesis risk from clinical trials but failed to provide adequate warnings to patients and prescribing physicians. As a result, patients chose to take these medications without understanding the risk of a potentially permanent and disabling condition.
Frequently Asked Questions
Can I file a lawsuit if I stopped taking Ozempic and my gastroparesis improved?expand_more
Yes. You can file a claim for the period you suffered gastroparesis symptoms even if you have since improved. If the condition was severe enough to require hospitalization, cause significant suffering, or result in lost wages, you may have compensable damages regardless of your current status.
Do I need a gastroparesis diagnosis to file an Ozempic lawsuit?expand_more
You generally need a formal medical diagnosis of gastroparesis or a documented gastric emptying abnormality. Severe nausea and vomiting alone, without a confirmed gastroparesis diagnosis, typically does not meet the threshold for a strong lawsuit. An attorney can review your medical records to determine if your documented symptoms and test results support a claim.
Is Mounjaro (tirzepatide) included in these lawsuits?expand_more
Yes. Mounjaro and its weight-loss version Zepbound are manufactured by Eli Lilly and contain tirzepatide, which acts on both GLP-1 and GIP receptors. Lawsuits against Eli Lilly allege similar failures to warn about gastroparesis risk. An attorney can evaluate whether Mounjaro use supports a claim in addition to or instead of semaglutide-based drugs.
SuperLawsuits Editorial Team
Reviewed by licensed attorneys in our network